Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
Antonioli
Elisabetta
E
Carobbio
Alessandra
A
Pieri
Lisa
L
Pancrazzi
Alessandro
A
Guglielmelli
Paola
P
Delaini
Federica
F
Ponziani
Vanessa
V
Bartalucci
Niccolò
N
Tozzi
Lorenzo
L
Bosi
Alberto
A
Rambaldi
Alessandro
A
Barbui
Tiziano
T
Vannucchi
Alessandro M
AM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D019943:Amino Acid Substitution; D005260:Female; D005787:Gene Frequency; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
D019384:Nucleic Acid Synthesis Inhibitors; D053614:Janus Kinase 2; D006918:Hydroxyurea